Cytovale vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cytovale is developing a rapid point-of-care sepsis diagnostic — IntelliSep — that measures immune cell deformability via microfluidics to detect sepsis in ~8 minutes; received FDA Breakthrough Device Designation; raised $88M total;
About
Cytovale is a medical technology company headquartered in San Francisco, California, founded in 2014 by Lydia Sohn and others, with roots in biophysics research at the University of California, Berkeley. The company is developing the IntelliSep test — a rapid, near-patient diagnostic for sepsis that uses a proprietary microfluidic technology to measure the mechanical properties (deformability) of immune cells in whole blood. Sepsis — a life-threatening systemic immune response to infection — kills approximately 270,000 Americans annually and is the leading cause of hospital mortality, yet current diagnostic approaches (blood cultures, lactate, clinical scoring systems) are slow, non-specific, and frequently fail to identify sepsis before it progresses to organ failure and septic shock.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.